Moderna (MRNA)
(Delayed Data from NSDQ)
$147.92 USD
-5.28 (-3.45%)
Updated May 29, 2024 04:00 PM ET
After-Market: $146.89 -1.03 (-0.70%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$147.92 USD
-5.28 (-3.45%)
Updated May 29, 2024 04:00 PM ET
After-Market: $146.89 -1.03 (-0.70%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Uptick in Consumer Confidence Puts 3 Stocks on Top
by Zacks Equity Research
Consumer Confidence rose for the first time since February, reflecting Americans' optimism as the economy reopens.
Dow Touches 25,000 in More Than 2 Months: 4 Blue-Chip Picks
by Nalak Das
The blue-chip index's northbound journey began on Mar 24 and is continuing barring occasional fluctuations.
Here's How Americans Are Regaining Confidence: 5 Picks
by Sanghamitra Saha
U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.
5 Best Stocks of Dow ETF From Last Week
by Sweta Killa
The Dow Jones gained 3.3% last week, marking its best weekly performance since April 9.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
Stock Market News for May 26, 2020
by Zacks Equity Research
U.S. stocks ended mostly mixed on May 22, as investors tried to fathom the extent of U.S.-China tensions that rose earlier in the week.
Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial
by Kinjel Shah
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
Novavax Begins Clinical Study for Coronavirus Vaccine
by Zacks.com
Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.
2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks
by Tirthankar Chakraborty
As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.
Tap the Solid Momentum in These 5 Solid High-Beta Stocks
by Sanghamitra Saha
Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta stocks that are in high momentum should gain ahead.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Coronavirus Vaccine Development Gathers Steam: 4 Winners
by Ritujay Ghosh
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
Coronavirus Vaccine Race Pushes Up Pharma Giants' Production
by Ritujay Ghosh
Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.
Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Company News for May 21, 2020
by Zacks Equity Research
Companies In The News Are: MRNA, FB, CLX, RCL.
Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain
by Sweta Jaiswal, FRM
Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
Stock Market News for May 20, 2020
by Zacks Equity Research
U.S. stock markets closed lower on Tuesday following the news that a potential vaccine candidate for the treatment of the coronavirus may not be effective.
Moderna Declines on Skepticism on Coronavirus Vaccine Data
by Zacks Equity Research
Moderna (MRNA) shares decline following a report raising questions on clinical data announced earlier this week related to its coronavirus vaccine.
Moderna Rallies on Encouraging Coronavirus Vaccine Study Data
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.
Stock Market News for May 19, 2020
by Zacks Equity Research
Wall Street rebounded impressively on Monday buoyed by an encouraging early-stage clinical trial data for a potential coronavirus vaccine.
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up
by Ritujay Ghosh
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Major Indexes Defying "Sell in May" Adage: 5 Growth Picks
by Nalak Das
Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage "Sell in May and go away."
Here's Why Moderna (MRNA) Stock is Jumping Today
by Madeleine Johnson
On Monday, shares of biotech Moderna Inc. (MRNA) soared over 26% in midday trading, and closed up XX% to $X.
Buy Nvidia & Alibaba Stock Before Earnings for Coronavirus Resilience?
by Benjamin Rains
We dive into Nvidia and Alibaba ahead of their quarterly earnings results that are due out this week to help investors decide if either stock might worth buying...